Bharat Parenterals Ltd — Important, 21-04-2026: Company Update

Bharat Parenterals' subsidiary, Innoxel Lifesciences, recently underwent a surprise U.S. FDA inspection at its Vadodara injectables manufacturing facility. The inspection concluded with five observations classified as Voluntary Action Indicated (VAI). This block is crucial for supplying sterile injectable formulations to regulated markets, including the United States and European Union. Innoxel will submit its response to the FDA, with the final Establishment Inspection Report awaited. A VAI classification generally signifies procedural observations, reflecting the company's consistent quality and compliance systems for critical manufacturing operations.